Lucira Health, Inc. (LHDX)
Lucira Health, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in EmeryVille, CA, US. The stock last traded at $0.45, up 0.00% on the session, giving a market capitalisation of $18.4M. On trailing twelve-month figures it carries a trailing P/E of -0.24, a net margin of -69.7%. Its beta of 3.76 implies it has historically moved more than the broad market.
Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.
Lucira Health, Inc. is most often compared with the following Healthcare names: